Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL

Enrollment

109

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

May 24, 2016

Study Completion Date

May 24, 2016

Conditions

Systemic Lupus ErythematosusHealthy Volunteers

Interventions

DRUG

BIIB059 (litifilimab)

See Arm Descriptions

DRUG

Placebo

See Arm Descriptions

Trial Locations (5)

Research Site, Great Neck

Research Site, Duncansville

Research Site, Orlando

Research Site, Birmingham

Research Site, Anniston